Navigation Links
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
Date:9/21/2007

appetite, the amount of food eaten, and body weight. These are not all the side effects with BYETTA. A healthcare provider should be consulted about any side effect that is bothersome or does not go away.

For complete safety profile and other important prescribing considerations, visit http://www.BYETTA.com.

About Amylin and Lilly

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first- in-class medicines for diabetes. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help health care professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

This press release contains forward-looking statements about Amylin and Lilly. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that exenatide and the revenu
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014  The law firm McElroy, ... that it will serve as host for "Show ... the Risks of Healthcare Reform," a one-day conference ... delivery systems, reimbursement, compliance and enforcement in a ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  ...
(Date:9/17/2014)... Sept. 17, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... on licensing, developing and commercializing innovative biopharmaceutical products ... its public offering of 4,500,000 shares of its common stock ... per share. Aratana has granted the underwriters a ... 675,000 shares of its common stock. ...
(Date:9/17/2014)... CARLSBAD, Calif. , Sept. 17, 2014 /PRNewswire/ ... ) announced that it has earned a $4 ... AKAO ) associated with the initiation of ... with serious multi-drug resistant (MDR), gram-negative bacterial infections.  ... superiority study to evaluate the efficacy and safety ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
(Date:9/17/2014)... East Brunswick, NJ (PRWEB) September 17, 2014 ... its Static Application Security Testing (SAST) tool, at AppSec ... the 19th from 9 am to 6 pm at ... 2014 is one of the leading software security conferences ... SPARROW is a tool that provides developers and managers ...
(Date:9/17/2014)... Journal of Surgery ( IJS ) has announced that ... after 24 months published journal issues become available for all ... is to improve surgical knowledge and patient care and it ... will improve efforts to achieve this. , Professor David ... always been a great place for authors to publish and ...
(Date:9/17/2014)... coupled to a progressive decline in signal transduction and ... at Karolinska Institutet in Sweden. The finding, which is ... new molecular mechanism underlying age-related impairment of insulin-producing cells ... risk factors for many diseases, and type 2 diabetes ... an increased risk of developing type 2 diabetes if ...
(Date:9/17/2014)... Representatives with Capitol Pain Institute announced ... League Event at the Four Seasons in Austin, Texas. , ... honor to be a sponsor for this great event,” said ... went on to explain that the event, the Torch of ... members at the Four Seasons to honor Torch of Liberty ...
(Date:9/17/2014)... In a continuing effort to protect local athletes ... Shield of the South Shore has partnered for the ... Athletic Association to treat area fields in preparation for ... dusk, prime mosquito feeding time, the exposure to mosquito-borne ... involved in outdoor athletic activities. , Rob and Lisa ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:Mechanism behind age-dependent diabetes discovered 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2
... obstacles towards progress in the developing world is the ... been seriously addressed by the public health community. ... People, Forgotten Diseases, published by ASM Press. , Some ... too long been ignored. Parasitic and bacterial diseases ...
... Ohio, April 8, 2008 Cardinal Health,Inc. (NYSE: CAH ... safety and productivity of health care, plans to release third-quarter,results ... opening of trading,on the New York Stock Exchange., The ... 1 at,8:30 a.m. EDT to discuss results of the quarter. ...
... small trial, new study finds no effect , , TUESDAY, ... don,t help prevent relapses in patients with Crohn,s disease, ... of the Journal of the American Medical Association ... lead author Dr. Brian Feagan, professor of medicine and ...
... tea have long held a place in traditional medicine in ... health and long life and for the treatment of specific ... the bodys immune functions and hold the potential for treatment ... Now a new study by Chinese scientists found that combining ...
... 8, 2008 The numbers tell the,story, Vicki Hoak, ... the Senate Aging and Youth Committee today.,The Medicaid reimbursement ... is $67,000,per person. For an acute care hospital, the ... is just $21,000., Since the Governor and legislators ...
... Light San Diego Pink Day, SAN DIEGO, April ... world,s largest grassroots network of breast cancer survivors and,activists ... San Diego Affiliate will award $960,000 in grants to ... underinsured women and men in,San Diego receive breast cancer ...
Cached Medicine News:Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 2Health News:Cardinal Health to Announce Third-Quarter Results on May 1 3Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 2Health News:Omega-3 Fatty Acids Won't Prevent Crohn's Relapse 3Health News:Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 2Health News:Since Governor and Legislators Agree on Value of Homecare, Advocacy Group Says Time is Now to Make it Available to More Pennsylvanians 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 2Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 3Health News:Susan G. Komen for the Cure Awards San Diego Organizations Nearly $1 Million to Fight Breast Cancer 4
Prostate biopsy transducer....
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
... an excellent choice for a ... wide scan angle. With muliple ... designed for a wide view ... versatility of this transducer provides ...
Medicine Products: